Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M114,297Revenue (TTM) $M32,839Net Margin (%)52.8Altman Z-Score4.8
Enterprise Value $M129,421EPS (TTM) $11.7Operating Margin %65.4Piotroski F-Score5
P/E(ttm)7.3Beneish M-Score-2.4Pre-tax Margin (%)63.7Higher ROA y-yN
Price/Book8.810-y EBITDA Growth Rate %--Quick Ratio1.6Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %27.2Current Ratio1.8Lower Leverage y-yN
Price/Free Cash Flow7.3y-y EBITDA Growth Rate %32.4ROA % (ttm)38.1Higher Current Ratio y-yN
Dividend Yield %2.0PEG0.3ROE % (ttm)105Less Shares Outstanding y-yY
Payout Ratio %15.0Shares Outstanding M1,332ROIC % (ttm)76.6Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDJulian Robertson 2016-03-31 Reduce-4.65%$82.71 - $101.19
($90.37)
$ 85.82-5%Reduce -90.24%38,511
GILDLeon Cooperman 2016-03-31 Buy 1.26%$82.71 - $101.19
($90.37)
$ 85.82-5%New holding516,989
GILDDavid Dreman 2016-03-31 Buy 0.24%$82.71 - $101.19
($90.37)
$ 85.82-5%New holding23,210
GILDJoel Greenblatt 2016-03-31 Add0.1%$82.71 - $101.19
($90.37)
$ 85.82-5%Add 10.68%967,642
GILDNWQ Managers 2016-03-31 Reduce-0.08%$82.71 - $101.19
($90.37)
$ 85.82-5%Reduce -30.50%116,000
GILDJohn Rogers 2016-03-31 Add0.05%$82.71 - $101.19
($90.37)
$ 85.82-5%Add 3.58%1,360,492
GILDT Rowe Price Equity Income Fund 2016-03-31 Add0.04%$82.71 - $101.19
($90.37)
$ 85.82-5%Add 8.29%1,353,600
GILDKen Fisher 2016-03-31 Reduce-0.01%$82.71 - $101.19
($90.37)
$ 85.82-5%Reduce -13.63%487,030
GILDGeorge Soros 2016-03-31 Buy 0.01%$82.71 - $101.19
($90.37)
$ 85.82-5%New holding3,600
GILDMario Gabelli 2016-03-31 Reduce$82.71 - $101.19
($90.37)
$ 85.82-5%Reduce -4.71%40,690
GILDRonald Muhlenkamp 2016-03-31 Add$82.71 - $101.19
($90.37)
$ 85.82-5%Add 0.01%217,990
GILDFirst Eagle Investment 2016-03-31 Add$82.71 - $101.19
($90.37)
$ 85.82-5%Add 2200.00%9,200
GILDDodge & Cox 2016-03-31 Add$82.71 - $101.19
($90.37)
$ 85.82-5%Add 103.20%7,620
GILDT Rowe Price Equity Income Fund 2015-12-31 Buy 0.57%$97.54 - $110.96
($104.15)
$ 85.82-18%New holding1,250,000
GILDJulian Robertson 2015-12-31 Add0.55%$97.54 - $110.96
($104.19)
$ 85.82-18%Add 11.95%394,411
GILDDavid Dreman 2015-12-31 Sold Out -0.11%$97.54 - $110.96
($104.19)
$ 85.82-18%Sold Out0
GILDJohn Keeley 2015-12-31 Sold Out -0.08%$97.54 - $110.96
($104.19)
$ 85.82-18%Sold Out0
GILDJoel Greenblatt 2015-12-31 Reduce-0.06%$97.54 - $110.96
($104.19)
$ 85.82-18%Reduce -6.70%874,246
GILDDodge & Cox 2015-12-31 Reduce$97.54 - $110.96
($104.19)
$ 85.82-18%Reduce -11.76%3,750
GILDKen Fisher 2015-12-31 Add$97.54 - $110.96
($104.15)
$ 85.82-18%Add 0.27%563,917
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MILLIGAN JOHN FPresident and CEO 2016-05-02Sell112,000$87.71-2.15view
MARTIN JOHN CExecutive Chairman 2016-05-02Sell100,000$87.82-2.28view
Carter Paul RutherfordEVP Commercial Ops 2016-05-02Sell2,000$88.72-3.27view
Alton Gregg HEVP, Corp & Med Affairs 2016-04-19Sell40,000$100.01-14.19view
MILLIGAN JOHN FPresident and CEO 2016-04-04Sell112,000$94.59-9.27view
Carter Paul RutherfordEVP Commercial Ops 2016-04-01Sell2,000$91.34-6.04view
MARTIN JOHN CExecutive Chairman 2016-04-01Sell100,000$93.24-7.96view
Alton Gregg HEVP, Corp & Med Affairs 2016-04-01Sell5,000$91.23-5.93view
Alton Gregg HEVP, Corp & Med Affairs 2016-03-14Sell5,000$90-4.64view
Carter Paul RutherfordEVP Commercial Ops 2016-03-01Sell2,000$87.9-2.37view

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016 
Endonovo Therapeutics: Innovative Treatment, Catalyst Create Compelling Opportunity May 22 2016 
Gilead Sciences Appears to Have Bottomed: Time to Buy? May 20 2016 
Is Seasonal Investing the Best Way to Approach the Market? May 13 2016 
John Buckingham Touts Apple, Gilead, Amgen May 11 2016 
The PBM Empire Strikes Back May 10 2016 
There Are Many Reasons to be Optimistic About Gilead's Prospects May 03 2016 
Gilead, Fossil Among Stocks Trading Below Lynch Earnings Line Apr 13 2016 
Take 5: Consider Stocking Up on Gilead Sciences Apr 12 2016 
Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity Apr 10 2016 

More From Other Websites
A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version... May 29 2016
Gilead timeline May 29 2016
7:26 am Gilead Sciences confirms positive CHMP opinion for co's marketing authorization application... May 28 2016
Gilead Subpoenaed as Feds Probe Charity Connections May 27 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into... May 27 2016
Expected amount of compensation and settlement in the planned domination and profit transfer... May 27 2016
3 Stand-Out Health Care Stocks for Dividends and Growth May 27 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences... May 27 2016
Gilead Gets European CHMP's Positive Opinion For Epclusa For All Genotypes of Chronic Hepatitis C... May 27 2016
Gilead Sciences: Why HIV Sales Could Save the Day May 27 2016
EU regulators back approval of Gilead's new hep C drug May 27 2016
European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the... May 27 2016
EU regulators recommend approving Gilead's new hepatitis C drug May 27 2016
European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the... May 27 2016
Gilead Subpoenaed as Feds Probe Drugmaker-Charity Connections May 27 2016
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016
Investors Eager for Gilead to Make Big Moves May 26 2016
Biotech Giant Gilead Sciences Goes on Sale May 26 2016
Please Gilead, Celgene and Amgen. Don't Buy Medivation. May 26 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)